دورية أكاديمية
1501TiP A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
| العنوان: | 1501TiP A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01) |
|---|---|
| المؤلفون: | Lugini, A., Goldman, J.W., Tanizaki, J., Akamatsu, H., Xia, S., Ratajczak, C., Li, M., Bolotin, E., Seraj, J., Lu, S. |
| المصدر: | In Annals of Oncology October 2023 34 Supplement 2:S845-S845 |
| قاعدة البيانات: | ScienceDirect |
| تدمد: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2532 |